Please select the option that best describes you:
Do you offer hormonal therapy in combination with an anti-HER2 T-DM1 or T-DXd in metastatic breast cancer?
Answer from: Medical Oncologist at Community Practice
The hormone receptor-positive, HER2-positive (HR+/HER2+) breast cancer subtype is a distinct clinical entity from hormone receptor-negative, HER2-positive (HR−/HER2+) breast cancer. Moreover, there is heterogeneity among HR+/HER2+ tumors. The main oncogenic driver may vary among HR+/HER2+ pati...
Sign in or Register to read more